Arrowhead Pharmaceuticals' Ken Myszkowski To Retire As CFO; Daniel Apel Appointed As New CFO

On, April 9, 2025 Ken Myszkowski notified Arrowhead Pharmaceuticals, Inc. (the "Company") of his decision to retire as Chief Financial Officer of the Company, effective as of May 13, 2025 (the "Effective Date"). Mr. Myszkowski has served as the Company's Chief Financial Officer since 2009, and the Company extends its gratitude to Mr. Myszkowski for his years of service and contributions to the Company. Mr. Myszkowski's decision to retire was not the result of any disagreement with the Company.

 

Following the Effective Date, Mr. Myszkowski will serve as an employee adviser and provide transition services, as requested by the Company, to facilitate an effective transition of his job responsibilities to his successor, until January 31, 2026 (the "Transition Period"). In consideration for such services, Mr. Myszkowski will receive (i) a base salary at an annual rate of $200,000 through the end of the Transition Period, subject to his continued employment, (ii) continued eligibility to participate in the Company's medical, dental and life insurance benefit plans through the end of the Transition Period, subject to continued employment, and (iii) continued vesting of certain outstanding equity awards.

 

Appointment of Chief Financial Officer

 

On April 9, 2025, the Company determined that it would appoint Daniel Apel to serve as Chief Financial Officer of the Company, effective as of May 13, 2024, until the earliest of Mr. Apel's removal, termination, or resignation from such office.